Diamond Biotechnology Co., Ltd. (6815) Stock Statistics & Valuation Metrics
Total Valuation
Diamond Biotechnology Co., Ltd. has a market cap or net worth of TWD 754.41M. The enterprise value is ―.
- Market Cap
- TWD 754.41M
- Enterprise Value
- ―
Share Statistics
Diamond Biotechnology Co., Ltd. has 39,705,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 39,705,650
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Diamond Biotechnology Co., Ltd.’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -8.42%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.08
- Return on Invested Capital (ROIC)
- -8.42%
- Return on Capital Employed (ROCE)
- -0.10
- Revenue Per Employee
- 11.14M
- Profits Per Employee
- -1.56M
- Employee Count
- 45
- Asset Turnover
- 0.58
- Inventory Turnover
- 3.77
Valuation Ratios
The current PE Ratio of Diamond Biotechnology Co., Ltd. is -16.28. Diamond Biotechnology Co., Ltd.’s PEG ratio is 0.05.
- PE Ratio
- -16.28
- PS Ratio
- 1.42
- PB Ratio
- 1.36
- Price to FCF
- 8.07
- Price to Operating Cash Flow
- 9.17
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Diamond Biotechnology Co., Ltd. had revenue of 501.49M and earned -70.31M in profits. Earnings per share was -1.78.
- Revenue
- 501.49M
- Gross Profit
- 155.25M
- Operating Income
- -74.19M
- Pretax Income
- -79.84M
- Net Income
- -70.31M
- EBITDA
- -45.94M
- Earnings Per Share (EPS)
- -1.78
Cash Flow
In the last 12 months, operating cash flow was 85.19M and capital expenditures -3.23M, giving a free cash flow of 81.96M billion.
- Operating Cash Flow
- 85.19M
- Free Cash Flow
- 81.96M
- Free Cash Flow per Share
- 2.07
Dividends & Yields
Diamond Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 0.88%
- Dividend Per Share
- ―
- Dividend Yield
- 0.88%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 12.85%
- Earnings Yield
- -6.31%
Stock Price Statistics
- Beta
- -0.05
- 52-Week Price Change
- -71.68%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 22.98
- Average Volume (3m)
- 19.53K
Financial Position
Diamond Biotechnology Co., Ltd. as a current ratio of 3.28, with Debt / Equity ratio of 43.15%
- Current Ratio
- 3.28
- Quick Ratio
- 2.67
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- -1.91
- Interest Coverage Ratio
- -14.30
Taxes
In the past 12 months, Diamond Biotechnology Co., Ltd. has paid -9.53M in taxes.
- Income Tax
- -9.53M
- Effective Tax Rate
- 0.12
Enterprise Valuation
Diamond Biotechnology Co., Ltd. EV to EBITDA ratio is -37.28, with an EV/FCF ratio of 8.03.
- EV to Sales
- 1.42
- EV to EBITDA
- -37.28
- EV to Free Cash Flow
- 8.03
- EV to Operating Cash Flow
- 7.72
Balance Sheet
Diamond Biotechnology Co., Ltd. has TWD 249.67M in cash and marketable securities with TWD 203.96M in debt, giving a net cash position of TWD 45.70M billion.
- Cash & Marketable Securities
- TWD 249.67M
- Total Debt
- TWD 203.96M
- Net Cash
- TWD 45.70M
- Net Cash Per Share
- TWD 1.15
- Tangible Book Value Per Share
- TWD 14.49
Margins
Gross margin is 38.84%, with operating margin of -9.27%, and net profit margin of -10.23%.
- Gross Margin
- 38.84%
- Operating Margin
- -9.27%
- Pretax Margin
- -10.96%
- Net Profit Margin
- -10.23%
- EBITDA Margin
- -3.80%
- EBIT Margin
- -9.37%
Analyst Forecast
The average price target for Diamond Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -33.45%
- EPS Growth Forecast
- -246.29%
